AMGN has presented data in this patient population on time to first SRE and the rate of (first and subsequent) SREs for patients on Xgeva and Zometa (#msg-46426917).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”